Literature DB >> 25212882

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Robert A Kyle1, Jesus F San-Miguel2, Maria-Victoria Mateos3, S Vincent Rajkumar4.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is characterized by an M spike less than 3 g/dL and a bone marrow containing fewer than 10% plasma cells without evidence of CRAB (hypercalcemia, renal insufficiency, anemia, or bone lesions). Light chain MGUS has an abnormal free light chain (FLC) ratio, increased level of the involved FLC, no monoclonal heavy chain, and fewer than 10% monoclonal plasma cells in the bone marrow. Smoldering multiple myeloma has an M protein of at least 3 g/dL and/or at least 10% monoclonal plasma cells in the bone marrow without CRAB features.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Light chain monoclonal gammopathy of undetermined significance; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Smoldering multiple myeloma

Mesh:

Substances:

Year:  2014        PMID: 25212882     DOI: 10.1016/j.hoc.2014.06.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  11 in total

1.  Monoclonal gammopathy of renal significance: systemic involvement by benign condition.

Authors:  Vincenzo L'Imperio; Paolo Fabbrini; Franco Ferrario; Federico Pieruzzi; Antonella Tosoni; Rinaldo Brivio; Enrico Maria Pogliani; Fabio Pagni
Journal:  Kidney Int       Date:  2015-07       Impact factor: 10.612

Review 2.  Smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Ola Landgren; María-Victoria Mateos
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 3.  Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.

Authors:  Hafsa M Chaudhry; Michelle L Mauermann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

Review 4.  How I manage monoclonal gammopathy of undetermined significance.

Authors:  Ronald S Go; S Vincent Rajkumar
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

5.  Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.

Authors:  Robert A Kyle; Dirk R Larson; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; James R Cerhan; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2018-01-18       Impact factor: 91.245

6.  Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies.

Authors:  Ai-Lin Zhao; Kai-Ni Shen; Ji-Nuo Wang; Lan-Qing Huo; Jian Li; Xin-Xin Cao
Journal:  Cancer Manag Res       Date:  2019-06-21       Impact factor: 3.989

7.  How to quantify monoclonal free light chains in plasma cell disorders: which mass spectrometry technology?

Authors:  Caroline Moreau; Charles R Lefevre; Olivier Decaux
Journal:  Ann Transl Med       Date:  2020-08

Review 8.  The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.

Authors:  Liesbeth Bieghs; Hans E Johnsen; Ken Maes; Eline Menu; Els Van Valckenborgh; Michael T Overgaard; Mette Nyegaard; Cheryl A Conover; Karin Vanderkerken; Elke De Bruyne
Journal:  Oncotarget       Date:  2016-07-26

9.  MALDI-TOF analysis of blood serum proteome can predict the presence of monoclonal gammopathy of undetermined significance.

Authors:  Francisca Barceló; Rosa Gomila; Ivan de Paul; Xavier Gili; Jaume Segura; Albert Pérez-Montaña; Teresa Jimenez-Marco; Antonia Sampol; José Portugal
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

Review 10.  Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.

Authors:  Michael H Tomasson; Mahmoud Ali; Vanessa De Oliveira; Qian Xiao; Yogesh Jethava; Fenghuang Zhan; Adam M Fitzsimmons; Melissa L Bates
Journal:  Int J Mol Sci       Date:  2018-11-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.